Find Funding Opportunities

Purpose. This program provides three to five years of mentored career development support to clinically trained faculty members in strong research environments to enable them to gain skills and experience in aging research under the guidance of a mentor or mentors, and to establish an independent program of research in this field. Clinically trained professionals or individuals with a clinical degree who are interested in further career development in biomedical research that is patient-oriented should refer to the Paul B. Beeson Mentored Patient-Oriented Research Development (K23) Award in Aging [AG-10-011].The program also includes an annual meeting that allows opportunities to partner with national mentors and fellow awardees. Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH K08 (Mentored Clinical Scientist Development Award). Funds Available and Anticipated Number of Awards. The FY 2010 anticipated amount is $1 million. The anticipated number of awards is 5 to 7.

Purpose. This program provides three to five years of mentored career development support to clinically trained faculty members in strong research environments who have made a commitment to focus their research endeavors on patient-oriented research. The award will enable them to gain skills and experience in aging research under the guidance of a mentor or mentors, and to establish an independent program of research in this field. Clinically trained professionals or individuals with a clinical degree who are interested in further career development in biomedical research that is not patient-oriented should refer to the Paul B. Beeson Clinical Scientist Career Development Award in Aging (K08) [AG-10-010].The program also includes an annual meeting that allows opportunities to partner with national mentors and fellow awardees. Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the Mentored Patient-Oriented Research Career Development Award (K23) mechanism. Funds Available and Anticipated Number of Awards. The FY 2010 anticipated amount is $1 million. The anticipated number of awards is 5 to 7.

Purpose. This Funding Opportunity Announcement (FOA) requests applications for exploratory/developmental translational research on therapeutics for reducing mortality and morbidity caused by acute exposures to chemical threat agents. Chemical threats include traditional chemical warfare nerve agents such as sarin and VX, toxic industrial chemicals such as cyanide and chlorine, and toxic agricultural chemicals such as parathion and sodium fluoroacetate. Projects supported by this FOA are expected to generate preliminary data that would enable the development of competitive applications for more extensive support from the NIH CounterACT program (see www.ninds.nih.gov/counteract for a description) and other related research and development programs. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

Purpose. Participating Institutes and Centers of the NIH invite applications for R01 awards to support Bioengineering Research Grants (BRGs) for basic and applied multi-disciplinary research that addresses important biological, bioengineering or medical research problems. The BRGs support multi-disciplinary research performed in a single laboratory or by a small number of investigators that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism and runs in parallel with a FOA of similar scientific scope, Exploratory/Developmental Bioengineering Research Grants, PA-10-010, that encourages applications under the R21 mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Purpose. This Funding Opportunity Announcement (FOA) is intended to encourage innovation and high risk/impact bioengineering research in new areas. While minimal or no preliminary data are expected to be described in the application, applications should clearly indicate the significance of the proposed work and that the proposed research and/or development is scientifically sound, that the qualifications of the investigators are appropriate, and that resources available to the investigators are adequate. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research. The research proposed under this program can explore approaches and concepts new to a particular substantive area; research and development of new technologies, techniques or methods; or initial research and development of data upon which significant future research may be built. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOA of similar scientific scope, PA-10-009 Bioengineering Research Grants, and PAR-07-352, Bioengineering Research Partnerships. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

Purpose. The National Institute of Neurological Disorders and Stroke (NINDS) invites new and competing renewal applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. Proposed Centers must involve multidisciplinary teams engaged in integrative basic, translational and clinical research on Parkinsons disease (PD), with the primary objective of transforming this research into the development of new treatments. Investigations on related parkinsonian disorders may be included, to the extent that these inform and/or expand research on PD. Accomplishment of the stated goals of the Center, and of each project, must require substantial collaborative efforts and the utilization of common resource cores. All proposed Centers must include a pre-clinical and/or clinical translational research project. In this context, pre-clinical translation is defined as pre-IND/IDE (Investigational New Drug/Investigational Device Exemption) stage research on potential therapeutic or diagnostic candidates. Clinical translational projects are early-stage projects in human subjects that are designed as first steps toward transformation of scientific discoveries arising from basic research, clinical research or population studies into new modalities for the prevention, treatment and cure of PD. All Centers are required to have an Administrative Core; inclusion of other research and core components is flexible within stated budget limits. Inclusion of a clinical component, a clinical translational research project plus a clinical resource core, is encouraged, as is emphasis on training and public outreach activities. The Udall Center Director (PI) must be an established leader in scientific research with visionary leadership skills and proven expertise in research project and personnel management. Eligible institutions must demonstrate commitment to and support for the establishment and continuation of the proposed Udall Center. Successful applicants will participate in a network of existing Udall Centers to foster the translation of new scientific findings and technological developments into novel treatments for PD.

Purpose. The purpose of this Funding Opportunity Announcement (FOA), Mechanisms, Models, Measurement, and Management in Pain Research, issued by the National Institute of Nursing Research (NINR), in conjunction with members of the NIH Pain Consortium as listed above, is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute insult is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Mechanism of Support. This FOA will utilize the NIH Small Research Grant (R03) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-10-006, which encourages applications under the NIH R01 Research Project Grant mechanism and PA-10-007 which encourages applications under the R21 Exploratory/Developmental Grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.

Purpose. The purpose of this Funding Opportunity Announcement (FOA), Mechanisms, Models, Measurement, and Management in Pain Research issued by the National Institute of Nursing Research (NINR), in conjunction with members of the NIH Pain Consortium as listed above, is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute insult is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-10-008, which encourages applications under the R03 Small Research Grant mechanism and PA-10-007, which encourages applications under the R21 Exploratory/Developmental Grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Purpose. The purpose of this Funding Opportunity Announcement (FOA), Mechanisms, Models, Measurement, and Management in Pain Research, issued by the National Institute of Nursing Research (NINR), in conjunction with members of the NIH Pain Consortium as listed above, is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute insult is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-10-006, which encourages applications under the NIH R01 Research Project Grant mechanism and PA-10-008, which encourages applications under the R03 Small Research Grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

Purpose. The National Cancer Institute (NCI), the National Institute of Dental and Craniofacial Research (NIDCR), and the National Institute of Neurological Disorders and Stroke (NINDS), at the National Institutes of Health (NIH), invite new or renewal (competing) applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund 5-year P50 SPORE grants to support state-of-the-art investigator-initiated research that will contribute to improved detection, diagnosis, treatment, and prevention of an organ-specific cancer (or a related group of cancers). SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized research COREs, improved research model systems, and collaborative research projects with other institutions. The research supported through this program must be translational in nature and must always be based upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. Mechanism of Support. This FOA will utilize the NIH specialized center grant (P50) mechanism to fund up to approximately 10-20 new SPORE awards per year. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of sufficient number of meritorious applications.